Skip to Main Content

Paper Details

In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Leukemia
5
2022
BCL2, BRIP1, COPS2, Cas9, PDX, PDX samples, TP53, acute lymphoblastic leukemia, cancer, chromosomal, mice, patient, patient derived xenografts, patients, tumor, tumors, venetoclax
Author NameAffiliation
Ashok Kumar JayaveluMax Planck Institute of Biochemistry
Ashok Kumar JayaveluClinical Cooperation Unit Pediatric Leukemia, German Cancer Research Center
Frank WestermannGerman Cancer Research Center (DKFZ)
Frank WestermannHopp Children's Cancer Center (KiTZ)
  • 1 - 4

Datasets

Release 1.2